Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure
NCT00941525 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 174
Last updated 2015-07-07
Summary
The purpose of this study is to determine whether 24-hour fluctuation of intraocular pressure (IOP) is associated with central corneal thickness (CCT) in subjects with ocular hypertension or open angle glaucoma and in age-matched controls. Also to evaluate whether mean IOP reduction as a response to latanoprost (0.005% Xalatan) is associated with CCT, after a 4-weeks period of treatment.
Also, to evaluate whether 24-hour fluctuation of IOP is associated with corneal hysteresis (CH) measured by Ocular Response Analyzer (ORA).
Conditions
Interventions
- DRUG
-
Latanoprost
1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
Sponsors & Collaborators
-
Aristotle University Of Thessaloniki
lead OTHER
Principal Investigators
-
Fotis Topouzis, MD · Aristotle University Of Thessaloniki
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-09-30
- Primary Completion
- 2014-07-31
- Completion
- 2014-07-31
Countries
- Greece
Study Locations
More Related Trials
-
Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma
NCT01580254 ·Status: UNKNOWN ·Phase: PHASE4
-
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389 ·Status: COMPLETED ·Phase: PHASE3
-
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
NCT00230763 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma
NCT01209624 ·Status: COMPLETED
-
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®
NCT00486252 ·Status: COMPLETED
-
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
NCT02792803 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00224289 ·Status: COMPLETED ·Phase: PHASE4
-
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
NCT00596791 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00287521 ·Status: COMPLETED ·Phase: PHASE2
-
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00872651 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00293800 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
NCT04737928 ·Status: COMPLETED ·Phase: NA
-
The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
NCT02754570 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
NCT01379144 ·Status: COMPLETED ·Phase: PHASE2
-
24-hour IOP-lowering Effect of 0.01% Bimatoprost
NCT01271686 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742 ·Status: COMPLETED ·Phase: PHASE1
-
Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate
NCT06730516 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
NCT00716742 ·Status: COMPLETED
-
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
NCT00051155 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00293787 ·Status: COMPLETED ·Phase: PHASE3
-
28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT02531152 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT02059278 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
NCT01430923 ·Status: UNKNOWN ·Phase: NA
-
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT02129673 ·Status: COMPLETED ·Phase: PHASE1/PHASE2